摘要
目的探讨CD30阳性的弥漫性LBCL的组织病理形态、免疫表型及临床预后的意义.方法参照WHO 2001年恶性淋巴瘤分类,对8例同时表达B细胞抗原及CD30抗原的弥漫性LBCL进行形态学观察、免疫组化标记及临床随访.结果 8例弥漫性LBCL免疫组化CD30阳性,阳性反应定位于胞膜,其中2例伴有核旁高尔基区点状阳性,1例合并ALK呈粗大颗粒状胞质阳性,全部表达B系列抗原CD20、CD79α及CD138,2例EBV阴性,2例TIA-1阴性.组织学特征:3例呈窦性生长,2例呈明显的T/null间变性大细胞淋巴瘤的核型改变,3例以普通的中心母细胞性为主.临床以老年患者多见,4例随访4～28个月,1例仍在化疗,3例情况良好,4例失访.结论 CD30阳性的弥漫性LBCL具有嗜窦性,间变性或为普通性非间变性的组织细胞形态特征,可合并ALK阳性.
Purpose To explore the pathologic characterization, immunophenotype and prognosis of CD30-positive diffuse large B- cell lymphoma （LBCL）. Methods 8 cases of CD30-positive LBCL were selected according to 2001 WHO classification of tumors. Follow-up study and immunohistochemical staining for CD20, CD79α, CD3,CD45RO/UCHL1 ,CD45,CD5, CD30, CD138, ALK, bcl-2, CD10, bcl-6,EMA,TIA-1 ,κ/λwere carried out in the 8 cases. Results All 8 cases expressed CD30 with membrane staining, of 1 case also expressed ALK in cytoplasm. All cases showed B-cell markers such as CD20, CD79α and CD138 expression. 7 cases were positive for CD45. Histopathologically, 3 cases presented sinusoidal pattern, 2 cases had morphologic figures of anaplastic large cell lymphoma. 3 cacses had morphologic figures of central-blastic lymphoma. 4 - 28 months follow-up study for 4 cases showed that the patients were still alive. Conclusions CD30-positive LBCL is a clinicopathologic distinctive variant of diffuse large B-cell lymphomas, and may be co-express/on of ALK and CD30.
出处
《临床与实验病理学杂志》
CAS
CSCD
北大核心
2005年第6期655-658,共4页
Chinese Journal of Clinical and Experimental Pathology
